Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

QIAGEN Expands Product Portfolio for NGS and Cancer Research

Published: Saturday, April 05, 2014
Last Updated: Saturday, April 05, 2014
Bookmark and Share
New innovative product launches at AACR Annual Meeting add to broad portfolio of NGS solutions.

QIAGEN N.V. has announced two important new product launches which address workflow challenges in next-generation sequencing (NGS) applications.

QIAGEN will present these and several other innovative solutions for NGS applications at the American Association for Cancer Research (AACR) Annual Meeting from April 5-9 in San Diego, with about 35 poster and other sessions featuring applications of QIAGEN’s Sample & Assay Technologies.

The innovative QIAxpert® instrument accelerates quantification and quality control of DNA and RNA samples for next-generation sequencing (NGS), while the new CLC Cancer Research Workbench is the first complete bioinformatics software suite for rapid analysis, user-friendly visualization, and accurate interpretation of advanced NGS data in cancer research.

“Our portfolio of universal products for NGS includes innovative solutions for many of the key workflow challenges our customers face in sample preparation. QIAxpert and QIAxcel can assure the highest sample quality, saving time and costs by reducing the risk of having to repeat NGS experiments, and thus helping laboratories to generate valuable insights,” said Peer M. Schatz, Chief Executive Officer of QIAGEN.

Schatz continued, “In addition, our industry-leading bioinformatics portfolio is providing a new dimension of utility for our customers, as our commercial software solutions offer highest quality and performance, helping to accelerate NGS workflows and remove variability. The new CLC Cancer Research Workbench offers scientists and clinicians state-of-the-art analysis and interpretation of gene variants and cancers. At AACR, we will show these products plus new data for our GeneRead™ gene panels - all of which maximize NGS performance for all major platforms.”

QIAxpert is a high-speed UV/VIS spectrophotometer that enables laboratories to effortlessly assess the quality and quantity of nucleic acids in up to 16 samples within just two minutes. The QIAxpert employs intuitive software and an interactive touchscreen.

Pre-installed smart analysis applications can quantify both DNA and RNA with advanced spectral protocols to accurately differentiate molecules in complex samples, providing a comprehensive analytical profile.

QIAxpert aligns well with QIAxcel, QIAGEN’s capillary electrophoresis platform for DNA/RNA fragment analysis, ensuring the best quality in nucleic acid sample preparation for NGS.

The CLC Cancer Research Workbench is the world's first comprehensive, cancer-focused bioinformatics solution that can be modified or personalized by researchers. Its user-friendly software enables researchers to identify prognostic markers, identify sub-clonal somatic mutations, detect inherited traits, find biomarkers for drug response, and determine new oncogenes.

Advanced re-sequencing tools, in combination with an intuitive graphical user interface, provide rapid analysis and accurate interpretation of advanced NGS data. The CLC Cancer Research Workbench also enables all results to be filtered, visualized, and compared with relevant databases like COSMIC, ClinVar, or in-house curated ones, as well as with other datasets, in order to provide valuable insights and guide user research.

QIAGEN spotlight presentation at the AACR meeting

At the AACR meeting, QIAGEN will host an exhibitor spotlight presentation, “Revolutionize Your NGS Workflow with QIAGEN’s Platform-Agnostic Sample to Insight Solution,” from 10-11 a.m. on Tuesday April 8 in Exhibit Hall A of the San Diego Convention Center.

The workshop will offer new data on the ability of the GeneRead™ panels to identify known and novel mutations in paired tumor and normal formalin-fixed paraffin-embedded samples.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

QIAGEN Expands Leadership in Liquid Biopsies
QIAGEN and Tokai Pharmaceuticals to co-develop and commercialize the first regulated CTC-based companion diagnostic to guide treatments in prostate cancer.
Tuesday, March 17, 2015
QIAGEN Collaborates with Allele Frequency Community
QIAGEN providing secure bioinformatics infrastructure and software for research and clinical labs to contribute and gain insights from Allele Frequency Community.
Wednesday, February 25, 2015
QIAGEN, AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic
The collaboration is to advance EGFR mutation profiling in lung cancer patients.
Monday, July 28, 2014
QIAGEN Licenses Blood Cancer Biomarkers
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers.
Saturday, July 26, 2014
QIAGEN Receives FDA Approval for CMV Assay
Assay offers faster quantification of CMV DNA levels in patient samples.
Friday, June 20, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
QIAGEN Integrates Content from BIOBASE
The new content expands the world’s most comprehensive, high-quality and up-to-date literature source for clinical research and diagnosis.
Wednesday, May 21, 2014
QIAGEN Reports Fourth Quarter and Full-Year 2013 Results
Company reports adjusted net sales OF $1.31 billion for 2013 with growth in all regions and customer classes.
Thursday, January 30, 2014
QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Companion Diagnostics
Several lymphoma-related biomarkers, including EZH2 Y641 gene mutations, rights acquired from British Columbia Cancer Agency.
Monday, June 10, 2013
QIAGEN Acquires Ingenuity Systems
Suite of web-based applications powered by a unique expert-curated Knowledge Base eases major bottlenecks to leveraging genomic data in research and clinical diagnostics.
Thursday, May 02, 2013
QIAGEN Achieves Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
U.S. launch of therascreen® KRAS RGQ PCR kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer.
Wednesday, July 11, 2012
QIAGEN Unveils Initiative to Create Next-generation Sequencing Portfolio
Company plans to offer sample-to-result workflows that integrate its sample preparation and assay products with a next-generation benchtop sequencer and new bioinformatics.
Tuesday, June 26, 2012
QIAGEN Receives FDA Clearances for Rotor-Gene Q MDx Instrument and Compatible Influenza A/B Assay
Both products receive 510(k) clearance for in vitro diagnostic use in the U.S..
Tuesday, April 17, 2012
QIAGEN Expands Access to State-of-the-Art HPV Screening in China
Coinciding with International Women’s Day, QIAGEN also joins fifth year of campaign to provide free HPV testing to underprivileged women in China.
Thursday, March 08, 2012
QIAGEN and Genome Diagnostics Expands Partnership to Develop Tests for Applications in Prevention and Personalized Healthcare
Extended HLA testing portfolio includes products to assess tolerance for Lumiracoxib and for the early detection of inflammatory diseases.
Friday, June 18, 2010
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!